OR27-04 Efficacy And Safety Results From The Randomized, Placebo-controlled Multicenter Trial With Teprotumumab In Chronic-Low Clinical Activity Score Thyroid Eye Disease Patients

Disclosure: R.S. Douglas: Consulting Fee; Self; Horizon, Immunovant, Viridian. Research Investigator; Self; Horizon. S. Couch: Research Investigator; Self; Horizon. S.T. Wester: Advisory Board Member; Self; Horizon. Consulting Fee; Self; Immunovant, Sling. Research Investigator; Self; Horizon. B.T....

Descripción completa

Detalles Bibliográficos
Autores principales: Douglas, Raymond S, Couch, Steven, Wester, Sara T, Fowler, Brian T, Liu, Catherine, Subramanian, Prem, Tang, Rosa, Nguyen, Quang T, Maamari, Robi N, Hsu, Kate, Karon, Michael, Stan, Marius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Thyroid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554583/
http://dx.doi.org/10.1210/jendso/bvad114.2055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554583/
http://dx.doi.org/10.1210/jendso/bvad114.2055

Ejemplares similares